4 Best Long-Term Performance Health Sector ETFs 1.3

Is the Health Sector a good place to invest?

The Health Care Select Sector SPDR® Fund (XLV) is the oldest and largest Health Sector ETF available. Its’ inception date was on December 16, 1998.

XLV vs S&P 500 index fund: January 1999 – August 2019

Source: https://www.portfoliovisualizer.com/

XLV vs SPY: December 22, 1998 – September 6, 2019

Source: https://www.koyfin.com/home Continue reading “4 Best Long-Term Performance Health Sector ETFs 1.3”

Best Long-Term Performance Health Sector ETFs 1.2

  • The oldest Health Sector ETF has outperformed an S&P 500 index fund by 1.90% CAGR over the last 19 years. This Health Sector ETF has also experienced less volatility than an S&P 500 index fund.
  • There are currently 35 ETFs in the Morningstar Category called Health. 16 of these funds are 10 years old or older.
  • The top performing Health Sector ETF has outperformed an S&P 500 index fund by 8.98% CAGR over the last 12 years.

Health Care Select Sector SPDR® Fund (XLV) vs S&P 500 index fund: January 1999 – September 2018

Source: https://www.portfoliovisualizer.com/

Continue reading “Best Long-Term Performance Health Sector ETFs 1.2”

Sold Some Of Our Biotech Equity Holdings Today (FBT)

We sold some of our Biotech holdings today. I don’t currently see any problems in this is industry or this particular ETF at this time. We only sold to use the funds in another endeavor. Price paid $89.36, price sold $117.12. The First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is still a great fund and I still recommend it to other investors. I wrote about FBT back in January 2017 and updated the charts in the article in May 2017 right here: Discovering Value in Growth Stock Funds: Biotech ETFs

Are Biotech Funds Buys Once Again?

Are Biotech Funds Buys Once Again?

While a number of market industries were fearful of a Trump Presidency, nowhere was the concern more prevalent than in the biotech and drug segment. After all, Trump came out several times against the pricing practices in the drug market, vowing to do something to make this a more affordable area…. (Read full article at Zacks.)